FATE compared with RGNX: revenue, margins and what each company keeps, and the suppliers and customers both name

FATEFate Therapeutics Inc

Mkt capRevenueRevenue

RGNXRegenxbio Inc.

Mkt capRevenueRevenue

Compare

FATEFate Therapeutics Inc

RGNXRegenxbio Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Co-movers

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Co-movers

daily closes · 501dMethod ›

Moved together

FATEwithRGNX

×0.34co-movement · RGNX on FATE · 501d

r 0.38scale to r 0.75

Shared co-movers3with FATEwith RGNX

RXRXRecursion Pharmaceuticals, Inc.r 0.42r 0.46

CRSPCRISPR Therapeutics AGr 0.41r 0.44

BEAMBeam Therapeutics Inc.r 0.37r 0.50

FATE, solidRGNX, hatched× = co-movement · βr = correlationBar = r to r 0.75Order: weaker of A and BSource: daily closes

FATEFate Therapeutics Inc

2.08▼−4.16%· post 2.08

Mkt cap$249.2MRevenue$2MQ2 FY26Revenue$7MFY25

RGNXRegenxbio Inc.

7.20▼−2.83%· post 7.20

ClosedOct 30 '26

Mkt cap$475.3MRevenue$108MQ2 FY26Revenue$170MFY25

Compare

ClosedOct 30 '26

FATEFate Therapeutics Inc

RGNXRegenxbio Inc.

2.08▼−4.16%post 2.08

Price

7.20▼−2.83%post 7.20

$249.2M

Mkt cap

$475.3M

Q2 FY26$2M

Revenue

$108MQ2 FY26

FY25$7M

Revenue

$170MFY25

FATE2.08▼−4.16%vsRGNX7.20▼−2.83%ClosedOct 30 '26